Sbir phase II proposal titled innovative and adaptive drug delivery system for enhanced neuroprotection and repair in traumatic brain injuries from penetrating trauma or open skull fractures in low…
Active Definitive Contract Awarded Last action
- Contract number
- HT942525CE032
- Awardee
-
Altrazeal Life Sciences Inc. UEI N24WUMUHT5V9
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,300,000
Award facts
- Opportunity
-
- HQ003420RBDST Solicitation number
- Contract value 100% obligated
- $1,299,999.92 Current and potential, with all options
- Completion date 49% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Addison, TX 75001, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,300,000 |
About this award
The Defense Health Agency awarded a $1.3 million Small Business Innovation Research (SBIR) Phase II contract to Altrazeal Life Sciences Inc., doing business as Uluru, on September 5, 2025. This firm fixed-price contract supports the development of an innovative and adaptive drug delivery system designed to enhance neuroprotection and repair in traumatic brain injuries resulting from penetrating trauma or open skull fractures in low-resource environments. The work will be performed at the contractor's facility in Addison, Texas, with an ultimate completion date of January 4, 2028. As a small business set-aside award, this contract reflects the Defense Health Agency's commitment to leveraging innovative solutions from small businesses to address critical military medical challenges.
Altrazeal Life Sciences, a medical equipment manufacturer specializing in drug delivery solutions and trauma care technologies based in Addison, Texas, has demonstrated sustained expertise in developing advanced medical technologies for federal defense applications. This Phase II award builds on the company's prior SBIR Phase I research and represents part of a broader portfolio of federally-funded medical technology initiatives focused on trauma treatment and wound management. The contract supports the company's mission to create cutting-edge solutions that address complex healthcare challenges in military and austere care settings, contributing to improved outcomes for service members and trauma patients in resource-constrained environments.
Description
Sbir phase II proposal titled innovative and adaptive drug delivery system for enhanced neuroprotection and repair in traumatic brain injuries from penetrating trauma or open skull fractures in low resource environments
Quick answers
Who was awarded contract HT942525CE032?
HT942525CE032 was awarded to Altrazeal Life Sciences Inc. by Defense Health Agency (Department of Defense) on September 5, 2025.
How much is contract HT942525CE032 worth?
The government has obligated $1,300,000 on HT942525CE032.
Was contract HT942525CE032 competed?
The extent of competition for HT942525CE032 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award